United Parcel Service (UPS) is making a significant investment of $48 million to enhance its capabilities in healthcare logistics by establishing 27 temperature-controlled facilities across the Americas, Europe, and Asia.
This move is in response to the increasing demand for temperature-sensitive medications, particularly biologics, which are projected to grow at an 8.3% compound annual growth rate and reach a market value of approximately $39.1 billion by 2033.
UPS aims to improve the speed and reliability of its cold-chain logistics, which is crucial for maintaining the efficacy of medications that require strict temperature control, such as GLP-1 drugs like Novo Nordisk's Wegovy and Ozempic.
UPS Healthcare President John Bolla emphasized that these investments reflect the company's commitment to enhancing patient outcomes by ensuring the safe delivery of innovative treatments.
The company's CEO, Carol Tomé, noted that healthcare logistics has become a top priority for UPS, contributing to record revenue growth in this segment, with the first quarter of this year marking a milestone of $3 billion in healthcare revenue.
This strategic investment positions UPS to capitalize on the expanding healthcare market and address the challenges associated with cold-chain storage, which currently sees significant waste, as highlighted by the World Health Organization's report on vaccine wastage